NeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene Editing

NeuBase Therapeutics Inc NBSE announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program, demonstrating the ability to achieve gene editing with a non-immunogenic system.

  • The data showed a dose-dependent increase in the correction of the gene mutation based on the expression of the new functional fluorescent protein compared with various controls, highlighting a titratable increase in efficiency with which the Stealth Editors can engage the genome to harness the cell's machinery to correct the mutation.
  • The results show that human peripheral blood mononuclear cells treated with a Stealth Editor did not impact cell viability. In addition, there was no cellular immune response for the Stealth Editor-treated cells compared with the control (PBS) across the five cytokines measured, in direct juxtaposition to the positive controls, which elicited a strong cytokine response.
  • Stealth Editors can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liver.
  • The company plans to present additional data showcasing the gene-editing capabilities of Stealth Editors throughout the remainder of 2023, including initial non-human primate and mouse data.

Price Action: NBSE shares are up 6.93% at $0.20 at the last check Monday.

Now Read: Nvidia Analyst Lifts Price Target Ahead Of Q1 Results: 'Should Warrant A Meaningful Premium vs Semiconductor Peers'




Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!